NCT07031674Completed
Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
The objective of this observational study is to compare the efficacy and safety of telitacicept and belimumab in the treatment of lupus nephritis in patients aged 18-65 years with lupus nephritis. The main question it aims to answer is: What are the response rates of the two drugs for the main renal therapy in the lupus nephritis population? Which drug has better efficacy and safety? This study is a retrospective study. The participants will not receive any treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 56 (actual)
- First submitted
- 13 Jun 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Yipeng Liu
- Diseases
- Lupus (SLE)
- NCT number
- NCT07031674
What you commit to
- Study type: Observational
- Participants enrolled: 56
- From 1 Oct 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received telitacicept or belimumab treatment for less than 12 weeks.
Other illness
- Having active central nervous system diseases;
Lab values
- eGFR \< 30 mL/min/1.73m², or undergoing hemodialysis or kidney transplantation;
Other
- Pregnant women, or those who are about to become pregnant in the near future, or lactating women;
- Participants who are simultaneously participating in other clinical studies;
Who the study is looking for
- Age range: 18 - 65 years old;
- Meets the revised SLE classification criteria of the American College of Rheumatology in 1997 or the SLE diagnostic classification criteria issued by EULAR/ACR in 2019;
- Urine protein quantification ≥ 1g/d, or urine PCR ≥ 1g/g, or qualitative urine protein test in urine routine ≥ 1+;
- Patients who have been using telitacicept or belimumab for at least 12 weeks.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qianfoshan Hospital Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.